Literature DB >> 29626276

Immunohistochemistry in Diagnostic Parathyroid Pathology.

Lori A Erickson1, Ozgur Mete2.   

Abstract

Pathologists are usually readily able to diagnose parathyroid tissues and diseases, particularly when they have knowledge of the clinical information, laboratory findings, and radiographic imaging studies. However, the identification of parathyroid tissue or lesions can be difficult in small biopsies, ectopic locations, supranumerary glands, and in some oxyphil/oncocytic lesions. Widely available immunohistochemical studies such as chromogranin-A, synaptophysin, keratin, parathyroid hormone, thyroglobulin, and thyroid transcription factor-1 can help in difficult cases. One of the most difficult diagnostic aspects faced by the pathologist in evaluating parathyroid is distinguishing between parathyroid adenoma, particularly atypical adenoma, and parathyroid carcinoma. Many markers have and continue to be evaluated for diagnostic utility, and are even beginning to be studied for prognostic utility. Single immunohistochemical markers such as parafibromin and Ki-67 are among the most studied and most utilized, but many additional markers have and continue to be evaluated such as galectin-3, PGP9.5, Rb, bcl2, p27, hTERT, mdm2, and APC. Although not widely available in many laboratories, a panel of immunohistochemical markers may prove most useful as an adjunct in the evaluation of challenging parathyroid tumors.

Entities:  

Keywords:  Atypical parathyroid adenoma; Immunohistochemistry; Parafibromin; Parathyroid; Parathyroid carcinoma; Parathyroid hormone

Mesh:

Substances:

Year:  2018        PMID: 29626276     DOI: 10.1007/s12022-018-9527-6

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  100 in total

1.  Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.

Authors:  E D Hsi; L R Zukerberg; W I Yang; A Arnold
Journal:  J Clin Endocrinol Metab       Date:  1996-05       Impact factor: 5.958

2.  HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.

Authors:  J D Carpten; C M Robbins; A Villablanca; L Forsberg; S Presciuttini; J Bailey-Wilson; W F Simonds; E M Gillanders; A M Kennedy; J D Chen; S K Agarwal; R Sood; M P Jones; T Y Moses; C Haven; D Petillo; P D Leotlela; B Harding; D Cameron; A A Pannett; A Höög; H Heath; L A James-Newton; B Robinson; R J Zarbo; B M Cavaco; W Wassif; N D Perrier; I B Rosen; U Kristoffersson; P D Turnpenny; L-O Farnebo; G M Besser; C E Jackson; H Morreau; J M Trent; R V Thakker; S J Marx; B T Teh; C Larsson; M R Hobbs
Journal:  Nat Genet       Date:  2002-11-18       Impact factor: 38.330

3.  Oxyphil parathyroid carcinomas: a clinicopathologic and immunohistochemical study of 10 cases.

Authors:  Lori A Erickson; Long Jin; Mauro Papotti; Ricardo V Lloyd
Journal:  Am J Surg Pathol       Date:  2002-03       Impact factor: 6.394

4.  Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.

Authors:  Janneke E Witteveen; Neveen A T Hamdy; Olaf M Dekkers; Job Kievit; Tom van Wezel; Bin T Teh; Johannes A Romijn; Hans Morreau
Journal:  Mod Pathol       Date:  2011-01-14       Impact factor: 7.842

5.  Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families.

Authors:  B T Teh; F Farnebo; S Twigg; A Höög; S Kytölä; E Korpi-Hyövälti; F K Wong; J Nordenström; L Grimelius; K Sandelin; B Robinson; L O Farnebo; C Larsson
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

6.  Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q.

Authors:  M R Hobbs; A R Pole; G N Pidwirny; I B Rosen; R J Zarbo; H Coon; H Heath; M Leppert; C E Jackson
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

7.  Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.

Authors:  A L Folpe; A M Gown; L W Lamps; R Garcia; D H Dail; R J Zarbo; R A Schmidt
Journal:  Mod Pathol       Date:  1999-01       Impact factor: 7.842

8.  Immunohistochemical Analysis of the Cell Cycle-Associated Antigens Ki-67 and Retinoblastoma Protein in Parathyroid Carcinomas and Adenomas.

Authors:  Ricardo V. Lloyd; J. Aidan Carney; Jorge A. Ferreiro; Long Jin; Geoffrey B. Thompson; Jon A. Van Heerden; Clive S. Grant; Peter C. Wollan
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

9.  GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.

Authors:  Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Janusz Rys; Piotr Czapiewski; Krzysztof Wazny; Renata Langfort; Piotr Waloszczyk; Wojciech Biernat; Jerzy Lasota; Zengfeng Wang
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

10.  Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.

Authors:  Daisuke Nonaka; Yunjia Tang; Luis Chiriboga; Michael Rivera; Ronald Ghossein
Journal:  Mod Pathol       Date:  2007-12-14       Impact factor: 7.842

View more
  26 in total

1.  Editorial: Special Issue on Immunohistochemical Biomarkers in Endocrine Pathology.

Authors:  Lori A Erickson; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

2.  Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas.

Authors:  Hasan Gucer; Sultan Caliskan; Mehmet Kefeli; Ozgur Mete
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

3.  Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms.

Authors:  Angelica M Silva-Figueroa; Roland Bassett; Ioannis Christakis; Pablo Moreno; Callisia N Clarke; Naifa L Busaidy; Elizabeth G Grubbs; Jeffrey E Lee; Nancy D Perrier; Michelle D Williams
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

Review 4.  Parathyroid Carcinoma: a Review.

Authors:  Shikhar Sawhney; Richa Vaish; Siddhanth Jain; Neha Mittal; Suman Kumar Ankathi; Shivakumar Thiagarajan; Devendra Chaukar
Journal:  Indian J Surg Oncol       Date:  2021-06-03

Review 5.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

Review 6.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 7.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 8.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Authors:  Guido Rindi; Ozgur Mete; Silvia Uccella; Olca Basturk; Stefano La Rosa; Lodewijk A A Brosens; Shereen Ezzat; Wouter W de Herder; David S Klimstra; Mauro Papotti; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2022-03-16       Impact factor: 3.943

Review 9.  Intratumor heterogeneity in human parathyroid tumors.

Authors:  C Verdelli; G S Tavanti; S Corbetta
Journal:  Histol Histopathol       Date:  2020-05-29       Impact factor: 2.303

10.  Distinguishing Parathyromatosis, Atypical Parathyroid Adenomas, and Parathyroid Carcinomas Utilizing Histologic and Clinical Features.

Authors:  Jefree J Schulte; Garrison Pease; Jerome B Taxy; Curtis Hall; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2021-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.